- Hepatic lipidosis in cats – a case study
- Background & Description
- Clinical examination
- Diagnostics
- Diagnosis: Hepatic lipidosis
- Treatment & Result
- Treatment at a glance
- Discussion
- background
- Primary vs. secondary hepatic lipidosis
- Clinical appearance
- Diagnostics
- Diagnosis
- Treatment
- Forecast
- Key findings
- FAQs about Hepatic Lipidosis in a Cat
- Summary of Hepatic Lipidosis in Cats
- Sources:
Hepatic lipidosis in cats – a case study
Background & Description
Pumpkin, a 7-year-old, 2.7 kg, spayed domestic cat, was presented to the emergency clinic after hiding in her foster home for a week. She had been placed there after being surrendered to a shelter. The foster carer could not determine whether Pumpkin had eaten or drunk anything. The evening before the presentation, the foster carer retrieved Pumpkin from her hiding place and offered her wet and dry food, but she showed no interest. No information was available regarding her history prior to being surrendered to the shelter.
Clinical examination
On clinical examination, Pumpkin was calm, alert, responsive, and anxious. Findings revealed a body condition score (BCS) of 2/5, dilated pupils, tachycardia (heart rate 208 bpm), urine staining on the pelvic extremities, icteric skin and sclera, and icteric and sticky mucous membranes. Dehydration was estimated at approximately 6–7 % based on prolonged skin turgor, capillary refill time was less than 2 seconds, and there were no signs of enophthalmic symptoms.
Diagnostics
The complete blood count (CBC) and serum chemistry (Table 1) showed mild, normocytic, normochromic, non-regenerative anemia, elevated ALT and ALP levels, hyperbilirubinemia, and hyperglycemia. Protein and electrolyte levels were within normal limits. Coagulation testing and urinalysis were unremarkable; the urine specific gravity was 1.041.
Table 1: Selected values from CBC & serum chemistry
| parameter | Result | Reference range |
|---|---|---|
| Hematocrit | 28 % | 30 %-45 % |
| OLD | 395 U/L | 45-217 U/L |
| ALP | 935 U/L | 11-95 U/L |
| Bilirubin | 7.2 mg/dL | 0-0.4 mg/dL |
| Glucose | 146 mg/dL | 60-133 mg/dL |
Abdominal ultrasound showed an enlarged liver with rounded caudoventral margins. The hepatic parenchyma appeared hyperechoic and hyperattenuated, suggestive of fatty deposition. Fine-needle aspiration of the liver revealed numerous hepatocytes with marked vacuolization, consistent with lipid accumulation (Figures 1 and 2).
Figure 1
Fine-needle aspirate from a cat's liver. Visible is a continuous sheet of numerous hepatocytes (solid arrows). The cytoplasm of almost all hepatocytes is strongly distended by large (macrovesicular) and small (microvesicular) clear vacuoles, which frequently obscure the nucleus and complicate the assessment of the hepatocytes. Numerous free lipid droplets are visible in the background (dashed arrows). Modified Wright stain, 200x magnification.
Figure 2
Fine-needle aspirate from a cat's liver. A continuous sheet of hepatocytes (solid arrows) is visible. The cytoplasm is markedly distended with clear vacuoles. Darkly pigmented material (bile casts; circles) between the cells indicates cholestasis. Numerous free lipid droplets (dashed arrow) are also present; however, this finding alone is not diagnostic, as intracellular lipids must be detected. Modified Wright stain, 600x magnification.
No underlying disease was identified, so primary hepatic lipidosis triggered by the stress of relocation was assumed.
Diagnosis: Hepatic lipidosis
Treatment & Result
Immediate hospitalization with intensive therapy was recommended but declined for financial reasons. Instead, a fluid bolus (0.9 mg/kg sodium chloride, 100 mL subcutaneously), vitamin K1 (1 mg/kg subcutaneously), and maropitant (1 mg/kg subcutaneously) were administered. Pumpkin was discharged with instructions to keep her in an enclosed area (e.g., a large cage, bathroom) to prevent nighttime hiding. She was to be given water but no food and return the following morning for placement of an esophagostomy tube (E-tube).
For placement of the endotracheal tube, Pumpkin was premedicated with butorphanol (0.3 mg/kg IM), induced with propofol (4 mg/kg IV), and oxygenated with isoflurane (1.5–2 %). The cat was positioned in right lateral recumbency, the left side of the neck was aseptically prepared, and the endotracheal tube was placed. The tube was secured with finger-trap sutures, closed, and the neck was bandaged to allow access for monitoring. Recovery from anesthesia was uneventful.
Energy requirements & feeding plan
The resting energy requirement (RER) was calculated as follows and was 183 kcal/day.
RER kcal/day = 70 × (optimal body weight in kg)^0.75
A commercially available therapeutic critical care diet, mixed with room-temperature water to a 1 kcal/mL gruel, was administered every 6 hours for 20 to 30 minutes during the first 3 days, and every 8 hours from day 4 onward. The feeding tube was flushed with water before (5 mL) and after (10 mL) each feeding. On the first day of treatment, 10 % of the RER were administered, divided into 4 feedings (i.e., 18.3 mL of the gruel). For the following 9 days, the ration was increased by 10 % daily until the full RER was reached. This frequency was maintained until Pumpkin began feeding independently. The details of the tailored feeding schedule are shown in Table 2.
Table 2: Tailor-made feeding plan
| day | % of the RER (183 kcal/day) | Total daily amount (mL) | Feeding frequency | Volume per feeding (mL) |
|---|---|---|---|---|
| 1 | 10 % | 18,3 | Every 6 hours | 4,57 |
| 2 | 20 % | 36,6 | Every 6 hours | 9,15 |
| 3 | 30 % | 54,9 | Every 6 hours | 13,7 |
| 4 | 40 % | 73,2 | Every 8 hours | 24,4 |
| 5 | 50 % | 91,5 | Every 8 hours | 30,5 |
| 6 | 60 % | 109,8 | Every 8 hours | 36,6 |
| 7 | 70 % | 128,1 | Every 8 hours | 42,7 |
| 8 | 80 % | 146,4 | Every 8 hours | 48,8 |
| 9 | 90 % | 164,7 | Every 8 hours | 54,9 |
| 10+ | 100 % | 183 | Every 8 hours | 61 |
Food was offered before each feeding via the E-tube.
Lactulose (0.5 mL orally every 6 hours for 3 days, then every 8 hours) was administered to prevent clinical signs of hepatic encephalopathy. After approximately 2 to 3 weeks, Pumpkin showed interest in food. The amount ingested was subtracted from the amount administered via the feeding tube. After another 2 to 3 weeks, she was able to consume her entire RER independently. Lactulose was discontinued, and the feeding tube was removed after she had eaten independently for 4 consecutive days.
Three weeks after the removal of the E-probe, Pumpkin was adopted by her foster parent and was described as healthy at the follow-up examination after three months.
Treatment at a glance
- Polyionic fluid therapy without lactate or dextrose is recommended.¹
- Electrolytes should be monitored and imbalances corrected.²
- Enteral nutrition is key to treatment.¹⁻⁵
- Force-feeding is not recommended, as it can lead to food aversion or aspiration pneumonia.²,⁵
- Cats with hepatic lipidosis usually require a nasogastric (only for inpatient care), esophageal, or gastrostomal feeding tube.² An esophageal tube is preferred for home feeding.
- A pureed diet with high protein, moderate fat, and minimal carbohydrates is crucial.³
- Feeding should be started slowly with small portions to avoid refeeding syndrome.³
- Appetite stimulants are not recommended.1,3
- Nutritional therapy can be lengthy and requires a significant commitment from the owners.³
- Relapse is rare in surviving cats.⁵
Discussion
Feline hepatic lipidosis (FHL) is the most frequently diagnosed hepatobiliary disease in cats. Previously considered idiopathic, it is now known to be caused by a negative energy balance.¹⁻⁵ The pathogenesis is not yet fully understood. FHL can affect cats of any breed, age, or sex, although middle-aged, overweight, or formerly overweight cats, as well as females, are overrepresented.¹,²
background
Cats are obligate carnivores and require a protein-rich diet with essential amino acids for their energy metabolism. Even a short period of loss of appetite or hyporexia can lead to metabolic disturbances.1,2 In a negative energy balance, lipase activity in peripheral adipose tissue is stimulated to release fatty acids into the bloodstream. These are taken up by the liver, oxidized, and either incorporated into VLDL (very-low-density lipoproteins) or stored intracellularly as triglycerides.1 In anorexic cats, most triglycerides are stored in liver vacuoles due to limited oxidative capacity and VLDL redistribution.
Excessive triglyceride accumulation leads to hepatocyte enlargement, increased liver weight, and altered liver architecture, resulting in cholestasis, jaundice, reduced metabolic capacity, and ultimately liver failure.¹⁻³ Cytological examinations show lipid vacuolization in more than 80 ¹TP3T hepatocytes.¹,²
Primary vs. secondary hepatic lipidosis
FHL can be primary or secondary. Primary FHL develops when external factors such as unpalatable food, environmental stress, or food insecurity lead to insufficient calorie intake. Secondary FHL accounts for 95% of cases and develops as part of another, progressive disease (e.g., neoplasms, diabetes mellitus, inflammation, or kidney disease) that leads to anorexia.²
Clinical appearance
Clinical signs include dehydration, nausea, hypersalivation, vomiting, jaundice, a dull coat, poor grooming, constipation, diarrhea, and a history of loss of appetite or weight loss.² Mental status may be altered depending on the stage of the disease, particularly in cases of hypokalemia, hyperammonemia, or hepatic encephalopathy. Cats with FHL are frequently hyperglycemic due to insulin resistance and increased production of counter-regulatory hormones.² Hypoglycemia in these cases is a sign of severe illness and indicates end-stage liver failure.
Diagnostics
Blood count parameters are often unremarkable. Nonspecific findings such as mild, non-regenerative anemia or leukocytosis may occur, but frequently depend on the underlying cause. Thrombocytopenia is not expected in primary FHL unless disseminated intravascular coagulation is present.²
Bleeding is common in cats with FHL, particularly during IV catheter placement, blood draws, liver biopsy, or tube insertion.² Vitamin K-dependent coagulation factors (II, VII, IX, X) are produced in the liver as non-functional precursors that require vitamin K for activation. Because vitamin K is fat-soluble and body stores are limited, regular dietary intake is necessary. Hepatobiliary disease can lead to secondary vitamin K deficiency due to inadequate fat digestion and absorption. In one study, 75 cats with FHL had elevated PIVKA (proteins induced by vitamin K deficiency) levels,¹ indicating widespread vitamin K deficiency in FHL. Therefore, prothrombin time and activated partial thromboplastin time are often prolonged in FHL patients.²
Diagnosis
The suspected diagnosis is often based on medical history, clinical examination, laboratory results, and imaging.² The definitive diagnosis is usually made by cytological examination of a fine-needle aspirate. This technique can usually be performed without general anesthesia and carries a lower risk of bleeding than a larger biopsy. However, if the fine-needle aspirate does not provide a diagnosis, a larger biopsy may be necessary.²
Treatment
Treatment is straightforward, but early initiation of therapy and close monitoring significantly improve the prognosis. Serum chemistry, urinalysis, CBC, and coagulation profiles should be performed in all suspected cases to guide therapy, determine severity, and identify potential causes.²,⁵
In cases of suspected fetal hepatic cholangiopancreatitis (FHL), prophylactic vitamin K1 (0.5–1.5 mg/kg IM or SC) should be administered to reduce the risk of bleeding during procedures.⁵ Rehydration (ideally IV) and electrolyte replacement are essential. Fluids without lactate or dextrose are preferred, as these can negatively affect hepatic lipid metabolism.¹ Once hydration and electrolyte levels are stabilized, a high-quality, high-protein (33–45 %), moderate-fat, and low-carbohydrate diet should be administered, preferably via a nasophageal tube (inpatient only), esophagostomy (preferred for home use), or gastrostomy to ensure adequate caloric intake.³
Too rapid an increase in food intake can lead to refeeding syndrome and cause severe, life-threatening electrolyte imbalances. An initial continuous infusion of small amounts may be helpful.13 Appetite stimulants are not recommended due to unpredictable results, altered liver metabolic activity, and masking effects.1,13
Feeding should begin with a maximum of 20 % of the calculated RER, divided into 4–5 small meals or administered as a continuous infusion.³ The amount is then increased daily by 10 %, while monitoring for signs of gagging or swallowing difficulties.³ If gagging or swallowing difficulties occur, the feeding amount should be reduced by 50 % for the next 12 hours.³ Antiemetics may be used, but the cause of the gagging should be investigated.³ The feeding should be warmed to room to body temperature before each feeding. A water bath is preferable to a microwave to ensure even heating. The feeding tube is flushed with 5 mL of water before each feeding to prevent blockages. It is also flushed with approximately 10 mL of water after feeding.³
The authors recommend that each feeding should last at least 20 to 30 minutes. Since Pumpkin responded well to feedings every 6 hours after a few days, the frequency was reduced to every 8 hours to improve adherence by the caregiver.
A study investigating the effect of diacylglycerol O-acyltransferase-1 inhibitors on triglyceride accumulation in FHL showed that the drug T863 reduced triglyceride accumulation by 52 %.⁶ Although the study was conducted ex vivo on feline liver organoids, it could potentially lead to future therapeutic options.
Forecast
Without treatment, the survival rate is only 5–20 %s. With therapy, the survival rate increases to 50–60 %s in secondary FHL and to an impressive 80–88 %s in primary FHL.²⁻⁴
The prognosis depends significantly on the presence of an underlying disease and the early initiation of enteral feeding. Owners should be informed that tube feeding requires a high level of cooperation and can last for 3–6 weeks.³ Relapses are rare in surviving cats.⁵
Key findings
- FHL is an excessive accumulation of triglycerides in the hepatocytes as a result of a negative energy balance and is the most common hepatobiliary disease in cats.
- FHL is life-threatening and requires rapid treatment.
- Middle-aged, overweight cats or those with a history of obesity are particularly at risk – but FHL can affect cats of any breed, age, or sex.1,2
- Early intervention is crucial for successful treatment.
- The chances of recovery are high, especially in primary FHL.
FAQs about Hepatic Lipidosis in a Cat
What is the most common cause of hepatic lipidosis in cats?
The most common cause of hepatic lipidosis is a negative energy balance, meaning that a cat consumes too little energy in the form of food over an extended period. Cats that suddenly stop eating due to external stressors such as moving, a new environment, a change in diet, or illness are particularly at risk. This so-called primary form of hepatic lipidosis occurs when no other underlying disease can be identified.
In addition, there is the secondary form, which accounts for approximately 95% of cases. This is a consequence of other diseases such as diabetes mellitus, chronic kidney disease, inflammation of the digestive tract, or tumors. These underlying diseases often cause the cat to become inappetent or stop eating altogether, which in turn leads to a massive release of fatty acids from body fat into the liver.
Whether primary or secondary, the crucial factor is that the cat remains malnourished for a certain period of time. Since cats, as obligate carnivores, are highly dependent on a continuous energy supply, they can develop the dangerous condition of hepatic lipidosis after just a few days of food refusal.
How can I recognize the early signs of hepatic lipidosis in my cat?
Early detection is crucial to significantly increase the chances of recovery. Typically, cats with early-stage hepatic lipidosis initially show nonspecific symptoms, which should nevertheless be taken seriously. These include, above all, loss of appetite or complete refusal to eat for more than 24–48 hours. This alone should be a warning sign, as cats are particularly sensitive to periods of food deprivation.
Other signs include weight loss, lethargy, weakness, or reduced activity. Increasing yellowing (jaundice) of the mucous membranes, gums, sclera (whites of the eyes), or skin also indicates liver involvement. Often, the coat becomes dull, the cat neglects grooming, and vomiting or diarrhea may occur.
In later stages, the animal's general condition deteriorates drastically: neurological symptoms such as disorientation or seizures occur, caused by possible hepatic encephalopathy. Early recognition of these warning signs and immediate veterinary care can significantly slow or even stop the progression of the disease.
How is hepatic lipidosis diagnosed in cats?
The diagnosis of hepatic lipidosis is based on a combination of medical history, clinical examination, laboratory tests, and imaging procedures. Veterinarians pay particular attention to a history of loss of appetite or weight loss, as well as clinical symptoms such as jaundice or weakness.
Laboratory tests often reveal elevated liver enzymes (especially ALT and ALP), hyperbilirubinemia, hyperglycemia, and sometimes signs of mild anemia. Ultrasound examination also provides valuable information: an enlarged, hyperechoic liver suggests fatty infiltration.
For a definitive diagnosis, a fine-needle aspiration of the liver is usually performed. In this procedure, a small amount of liver tissue is extracted with a thin needle and examined microscopically. Numerous fat-filled vacuoles within the hepatocytes are characteristic. This minimally invasive procedure is low-risk and usually provides the crucial diagnosis quickly.
In addition, special coagulation tests to check for bleeding tendencies and the measurement of vitamin K-dependent factors can be performed, as many cats with FHL have a coagulation disorder.
What does the treatment for hepatic lipidosis look like, and how long does it last?
Treatment for hepatic lipidosis in cats is intensive, but the prognosis is good if started early. The focus is always on a controlled, gentle reintroduction of food intake. Since affected cats usually do not eat voluntarily, feeding via a feeding tube (usually an esophagostomy tube) is often necessary.
First, the cat's resting energy requirement (RER) is calculated, and the amount of food is gradually increased to avoid the dangerous refeeding syndrome. Usually, one starts with 10–20 % of the energy requirement and increases the amount daily by about 10 % until the full calorie intake is reached.
Alongside nutritional therapy, supportive measures such as fluid therapy, vitamin K supplementation to support coagulation, and medication for nausea or accompanying illnesses are administered. In some cases, lactulose is also used to minimize the risk of hepatic encephalopathy.
The total treatment duration varies considerably, but usually lasts several weeks – often between 3 and 6 weeks. Even after the feeding tube is removed, the cat's diet should be closely monitored and the cat checked regularly. The good news is that if the cat survives the acute phase and resumes eating independently, the prognosis is usually excellent, and relapses are rare.
Can I prevent hepatic lipidosis in my cat?
Yes, there are effective measures for preventing hepatic lipidosis – especially if your cat belongs to a risk group, for example, because it is overweight or suffers from a chronic illness. The most important preventative goal is to ensure that your cat eats regularly. Even a 24–48 hour fast should be taken seriously and checked by a veterinarian.
Weight management plays a crucial role: Overweight cats should be carefully brought down to a healthy weight, always under veterinary supervision. Rapid diets are dangerous and can trigger the very lipidosis one wants to prevent.
Minimizing stress is also an important factor. Changes such as moving, new family members (human or animal), or renovations should be handled as smoothly as possible so that your cat doesn't stop eating out of fear or insecurity. Especially with planned changes, it helps to stick with the familiar food and perhaps offer some tasty additions.
Last but not least: Regular health checks help to identify potential diseases early on that could trigger secondary hepatic lipidosis. With vigilance, good care, and timely intervention, the risk can be significantly reduced.
Summary of Hepatic Lipidosis in Cats
Hepatic lipidosis in cats is one of the most common and serious liver diseases that cat owners should be aware of. What makes it particularly insidious is that the Hepatic lipidosis in cats It often begins with gradual symptoms and is therefore unfortunately frequently recognized too late. A sudden loss of appetite is one of the first warning signs of the Hepatic lipidosis in cats.
The cause of the Hepatic lipidosis in cats This is usually a negative energy balance, in which fat reserves are broken down from the body and stored in the liver. This overload of liver cells with fat is typical for the Hepatic lipidosis in cats and can quickly become life-threatening without timely treatment. Overweight animals are particularly susceptible. Hepatic lipidosis in cats, but cats of normal weight can also be affected.
The symptoms of Hepatic lipidosis in cats Symptoms are varied. They range from loss of appetite and weakness to jaundice. In many cases, cats with Hepatic lipidosis in cats Additionally, vomiting, lethargy, or neurological deficits may occur. Early detection of the Hepatic lipidosis in cats is therefore crucial for the success of the treatment.
For the diagnosis of Hepatic lipidosis in cats These include blood tests, an ultrasound of the liver, and a fine-needle aspiration. The latter usually reliably confirms the presence of a Hepatic lipidosis in cats, by making visible the fat-filled liver cells typical of this disease.
The therapy of Hepatic lipidosis in cats It is intensive, but promising. The cat is gradually reintroduced to sufficient calorie intake via a feeding tube. This is done in parallel during the... Hepatic lipidosis in cats Supportive therapy with fluids, electrolytes, and, if necessary, vitamin K. Careful feeding is the central element in the treatment of the Hepatic lipidosis in cats.
With patience and consistent care, many cats can recover. Hepatic lipidosis in cats fully survive. Especially if detected early. Hepatic lipidosis in cats The chances of recovery are an impressive 80 to 88 percent. Even in secondary cases. Hepatic lipidosis in cats, which is triggered by an underlying disease, the prognosis is good if the underlying disease is also treated.
Prevention also plays a key role. Those who identify the risk factors for the Hepatic lipidosis in cats Knowing this allows you to take early countermeasures. These include avoiding obesity, providing a stress-free environment, and immediately taking your pet to the vet if they lose their appetite. This helps reduce the risk of... Hepatic lipidosis in cats significantly reduce.
Pet owners should know: The Hepatic lipidosis in cats is not a death sentence. With timely diagnosis, intensive therapy, and good care, there is a long-term chance of survival. Hepatic lipidosis in cats a real chance of a full recovery.
The close cooperation with the Veterinary team is essential to monitor the course of the Hepatic lipidosis in cats to positively influence it. Patience and commitment pay off, because the Hepatic lipidosis in cats It requires weeks of care. But the effort is worthwhile: cats that Hepatic lipidosis in cats Those who survive usually return to a normal life.
In summary, it can be said that the Hepatic lipidosis in cats It is a serious but treatable condition. Attention in daily life, a quick response to initial symptoms, and sound medical care can prevent it from progressing. Hepatic lipidosis in cats takes on a life-threatening dimension.
The knowledge of the Hepatic lipidosis in cats It helps cat owners minimize risks and act quickly in an emergency. This is how the diagnosis becomes Hepatic lipidosis in cats Not fate, but a challenge that can be overcome on the way to a healthy cat life.
Sources:
- Center SA. Feline hepatic lipidosis. Vet Clin North Am Small Anim Pract. 2005;35(1):225-269. doi:10.1016/j.cvsm.2004.10.002
- Valtolina C, Favier RP. Feline hepatic lipidosis. Vet Clin North Am Small Anim Pract. 2017;47(3):683-702. doi:10.1016/j.cvsm.2016.11.014
- Armstrong PJ, Blanchard G. Hepatic lipidosis in cats. Vet Clin North Am Small Anim Pract. 2009;39(3):599-616. doi:10.1016/j.cvsm.2009.03.003
- Brown B, Mauldin GE, Armstrong J, Moroff SD, Mauldin GN. Metabolic and hormonal alterations in cats with hepatic lipidosis. J Vet Intern Med. 2000;14(1):20-26. doi:10.1892/0891-6640(2000)014<0020:mahaic>2.3.co;2
- Webb CB. Hepatic lipidosis: clinical review drawn from collective effort. J Feline Med Surg. 2018;20(3):217-227. doi:10.1177/1098612X18758591
- Haaker MW, Kruitwagen HS, Vaandrager AB, et al. Identification of potential drugs for treatment of hepatic lipidosis in cats using an in vitro feline liver organoid system. J Vet Intern Med. 2020;34(1):132-138. doi:10.1111/jvim.15670